| Dr Omkar Ulhas Vaidya, MD | |
|
65 Harrison Ave Ste 201, Boston, MA 02111-1924 | |
| (617) 513-8568 | |
| (913) 400-3631 |
| Full Name | Dr Omkar Ulhas Vaidya |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 17 Years |
| Location | 65 Harrison Ave Ste 201, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518117670 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beth Israel Deaconess Hospital Plymouth | Plymouth, MA | Hospital |
| Western Missouri Medical Center | Warrensburg, MO | Hospital |
| North Shore Medical Center - | Salem, MA | Hospital |
| South Shore Hospital | South weymouth, MA | Hospital |
| Sierra Vista Hospital | T or c, NM | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Western Missouri Medical Center | 7416931506 | 44 |
| Hillsdale Community Health Center | 7214846260 | 48 |
| Sierra Vista Hospital 69 | 0143122416 | 20 |
| Jordan Physician Associates Inc | 1254321086 | 153 |
| North Shore Physicians Group Inc | 3577467224 | 488 |
| Associated Physicians Of Harvard Medical Faculty Physicians At Beth Is | 6305749987 | 440 |
| Coastal Medical Associates | 7113029257 | 412 |
News Archive
Scientists at the University of North Carolina at Chapel Hill have found that a protein they discovered three years ago in the male reproductive tract is a potent anti-bacterial agent.
Medtronic announced today that the United States Court of Appeals for the Federal Circuit affirmed that the Pivot system offered by Globus Medical infringes two patents owned by Medtronic.
Many cancer therapies target specific proteins that proliferate on the outside of some cancer cells, but the therapies are imperfect and the cancer does not always respond. Since it is beneficial for doctors to know as soon as possible how a cancer is affected by treatment, researchers from Vanderbilt University are striving to design tests that assess treatment response rapidly, accurately, and cost-effectively.
Eventus Diagnostics, Inc. today announced completion of a $2.72 million financing. The financing was led by a new family office private investor, and existing investors also participated. Proceeds of the financing will mostly be used to support the continued development and commercialization of the company's Octava breast cancer tests.
Despite the great successes of targeted cancer drugs and the promise of novel immunotherapies, the vast majority of people diagnosed with cancer are still first treated with chemotherapy. Now a new study by UCSF researchers using techniques drawn from computational biology could make it much easier for physicians to use the genetic profile of a patient's tumor to pick the chemotherapy treatment with the fewest side effects and best chance of success.
› Verified 7 days ago
| Entity Name | Western Missouri Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083601330 PECOS PAC ID: 7416931506 Enrollment ID: O20040616000777 |
News Archive
Scientists at the University of North Carolina at Chapel Hill have found that a protein they discovered three years ago in the male reproductive tract is a potent anti-bacterial agent.
Medtronic announced today that the United States Court of Appeals for the Federal Circuit affirmed that the Pivot system offered by Globus Medical infringes two patents owned by Medtronic.
Many cancer therapies target specific proteins that proliferate on the outside of some cancer cells, but the therapies are imperfect and the cancer does not always respond. Since it is beneficial for doctors to know as soon as possible how a cancer is affected by treatment, researchers from Vanderbilt University are striving to design tests that assess treatment response rapidly, accurately, and cost-effectively.
Eventus Diagnostics, Inc. today announced completion of a $2.72 million financing. The financing was led by a new family office private investor, and existing investors also participated. Proceeds of the financing will mostly be used to support the continued development and commercialization of the company's Octava breast cancer tests.
Despite the great successes of targeted cancer drugs and the promise of novel immunotherapies, the vast majority of people diagnosed with cancer are still first treated with chemotherapy. Now a new study by UCSF researchers using techniques drawn from computational biology could make it much easier for physicians to use the genetic profile of a patient's tumor to pick the chemotherapy treatment with the fewest side effects and best chance of success.
› Verified 7 days ago
| Entity Name | Western Missouri Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578884144 PECOS PAC ID: 7113107699 Enrollment ID: O20110216000215 |
News Archive
Scientists at the University of North Carolina at Chapel Hill have found that a protein they discovered three years ago in the male reproductive tract is a potent anti-bacterial agent.
Medtronic announced today that the United States Court of Appeals for the Federal Circuit affirmed that the Pivot system offered by Globus Medical infringes two patents owned by Medtronic.
Many cancer therapies target specific proteins that proliferate on the outside of some cancer cells, but the therapies are imperfect and the cancer does not always respond. Since it is beneficial for doctors to know as soon as possible how a cancer is affected by treatment, researchers from Vanderbilt University are striving to design tests that assess treatment response rapidly, accurately, and cost-effectively.
Eventus Diagnostics, Inc. today announced completion of a $2.72 million financing. The financing was led by a new family office private investor, and existing investors also participated. Proceeds of the financing will mostly be used to support the continued development and commercialization of the company's Octava breast cancer tests.
Despite the great successes of targeted cancer drugs and the promise of novel immunotherapies, the vast majority of people diagnosed with cancer are still first treated with chemotherapy. Now a new study by UCSF researchers using techniques drawn from computational biology could make it much easier for physicians to use the genetic profile of a patient's tumor to pick the chemotherapy treatment with the fewest side effects and best chance of success.
› Verified 7 days ago
| Entity Name | Sierra Vista Hospital 69 |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760446009 PECOS PAC ID: 0143122416 Enrollment ID: O20211020002876 |
News Archive
Scientists at the University of North Carolina at Chapel Hill have found that a protein they discovered three years ago in the male reproductive tract is a potent anti-bacterial agent.
Medtronic announced today that the United States Court of Appeals for the Federal Circuit affirmed that the Pivot system offered by Globus Medical infringes two patents owned by Medtronic.
Many cancer therapies target specific proteins that proliferate on the outside of some cancer cells, but the therapies are imperfect and the cancer does not always respond. Since it is beneficial for doctors to know as soon as possible how a cancer is affected by treatment, researchers from Vanderbilt University are striving to design tests that assess treatment response rapidly, accurately, and cost-effectively.
Eventus Diagnostics, Inc. today announced completion of a $2.72 million financing. The financing was led by a new family office private investor, and existing investors also participated. Proceeds of the financing will mostly be used to support the continued development and commercialization of the company's Octava breast cancer tests.
Despite the great successes of targeted cancer drugs and the promise of novel immunotherapies, the vast majority of people diagnosed with cancer are still first treated with chemotherapy. Now a new study by UCSF researchers using techniques drawn from computational biology could make it much easier for physicians to use the genetic profile of a patient's tumor to pick the chemotherapy treatment with the fewest side effects and best chance of success.
› Verified 7 days ago
| Entity Name | Arena Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023627940 PECOS PAC ID: 2769800887 Enrollment ID: O20240228004384 |
News Archive
Scientists at the University of North Carolina at Chapel Hill have found that a protein they discovered three years ago in the male reproductive tract is a potent anti-bacterial agent.
Medtronic announced today that the United States Court of Appeals for the Federal Circuit affirmed that the Pivot system offered by Globus Medical infringes two patents owned by Medtronic.
Many cancer therapies target specific proteins that proliferate on the outside of some cancer cells, but the therapies are imperfect and the cancer does not always respond. Since it is beneficial for doctors to know as soon as possible how a cancer is affected by treatment, researchers from Vanderbilt University are striving to design tests that assess treatment response rapidly, accurately, and cost-effectively.
Eventus Diagnostics, Inc. today announced completion of a $2.72 million financing. The financing was led by a new family office private investor, and existing investors also participated. Proceeds of the financing will mostly be used to support the continued development and commercialization of the company's Octava breast cancer tests.
Despite the great successes of targeted cancer drugs and the promise of novel immunotherapies, the vast majority of people diagnosed with cancer are still first treated with chemotherapy. Now a new study by UCSF researchers using techniques drawn from computational biology could make it much easier for physicians to use the genetic profile of a patient's tumor to pick the chemotherapy treatment with the fewest side effects and best chance of success.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Omkar Ulhas Vaidya, MD 8010 State Line Rd Ste 100, Prairie Village, KS 66208-3711 Ph: (913) 400-3957 | Dr Omkar Ulhas Vaidya, MD 65 Harrison Ave Ste 201, Boston, MA 02111-1924 Ph: (617) 513-8568 |
News Archive
Scientists at the University of North Carolina at Chapel Hill have found that a protein they discovered three years ago in the male reproductive tract is a potent anti-bacterial agent.
Medtronic announced today that the United States Court of Appeals for the Federal Circuit affirmed that the Pivot system offered by Globus Medical infringes two patents owned by Medtronic.
Many cancer therapies target specific proteins that proliferate on the outside of some cancer cells, but the therapies are imperfect and the cancer does not always respond. Since it is beneficial for doctors to know as soon as possible how a cancer is affected by treatment, researchers from Vanderbilt University are striving to design tests that assess treatment response rapidly, accurately, and cost-effectively.
Eventus Diagnostics, Inc. today announced completion of a $2.72 million financing. The financing was led by a new family office private investor, and existing investors also participated. Proceeds of the financing will mostly be used to support the continued development and commercialization of the company's Octava breast cancer tests.
Despite the great successes of targeted cancer drugs and the promise of novel immunotherapies, the vast majority of people diagnosed with cancer are still first treated with chemotherapy. Now a new study by UCSF researchers using techniques drawn from computational biology could make it much easier for physicians to use the genetic profile of a patient's tumor to pick the chemotherapy treatment with the fewest side effects and best chance of success.
› Verified 7 days ago
Kaitlyn My-tu Lam, MBBS Nephrology Medicare: Not Enrolled in Medicare Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-724-7738 | |
Kui Toh Gerard Leong, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit Street, Massachusetts General Hospital, Boston, MA 02114 Phone: 617-726-8862 | |
Ruma Rajbhandari, Nephrology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-525-6841 | |
Alaka Ray, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2066 | |
Meghan E Sise, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2862 | |
Aaron Dickstein, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Box 233, Boston, MA 02111 Phone: 617-636-5883 Fax: 617-636-9292 | |
Dr. Felicia Elizabeth Patch, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 801 Massachusetts Ave, Crosstown 2, Boston, MA 02118 Phone: 617-414-4376 Fax: 617-414-4676 |